ClinicalTrials.gg
TerminatedNCT05194735Updated Nov 9, 2026Results posted

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

A Phase 1/2 interventional study of Neoantigen specific TCR-T cell drug product and Aldesleukin (IL-2) in Gynecologic Cancer, Colorectal Cancer and Pancreatic Cancer, sponsored by Alaunos Therapeutics. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Alaunos Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.
Updated Nov 9, 2026Results publication addedPosted results revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,764th of 1,934
8 · median 64
Started
2022
with 126 others
Phase 1/2
267 of 2,342
67 open now
Registered
1,701st of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 1,764th largest by enrollment of the 1,934 interventional ones that give a count, is one of 127 that started in 2022, is one of 267 in phase 1/2, and was the 1,701st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.

Read the detailed description

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.

Screening was initially conducted under TCR001-002. TCR001-201 Protocol Amendment 4, approved by the IRB on 20 January 2023 and implemented at the site in February 2023, incorporated HLA typing and tumor neoantigen screening into TCR001-201. Eligibility required a matching tumor mutation and HLA restriction represented in the Sponsor's clinical TCR library.

The Phase I part of this study is a prospective, open-label, dose-escalation study of TCR-T cell drug product in patients with progressive or recurrent solid tumors who have failed standard therapy. The Phase II part is a prospective, open-label, single dose portion of the study. The planned Phase II portion was to begin after determination of the maximum tolerated dose or recommended Phase II dose in Phase I. The program closed during Phase I Arm A before that determination. Arm B and Phase II were not initiated, and no subject received interleukin-2 under this study.

Subjects with one of the following histologically confirmed solid tumors will be included:

  • Cohort 1: Gynecologic cancer (e.g., ovarian, endometrial)
  • Cohort 2: Colorectal cancer
  • Cohort 3: Pancreatic cancer
  • Cohort 4: Non-small cell lung cancer (NSCLC); NSCLC includes but is not limited to squamous cell carcinoma, adenosquamous carcinoma or adenocarcinomas
  • Cohort 5: Cholangiocarcinoma

Subject must have a tumor mutation and HLA typing combination that matches to at least one of the following TCRs in the Alaunos' library (mutation \& HLA type):

  • KRAS G12D \& HLA-A*11:01
  • KRAS G12D \& HLA-C*08:02
  • KRAS G12V \& HLA-A*11:01
  • KRAS G12V \& HLA-C*01:02
  • TP53 R175H \& HLA-A*02:01
  • TP53 R175H \& HLA-DRB1*13:01
  • TP53 R248W \& HLA-A*68:01
  • TP53 Y220C \& HLA-A*02:01
  • TP53 Y220C \& HLA-DRB3*02:02
  • EGFR E746-A750del \& HLA-DPA1*02:01, DPB1*01:01
03

Conditions studied

  • Gynecologic Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Non-small Cell Lung Cancer
  • Cholangiocarcinoma
  • Ovarian Cancer
  • Endometrial Cancer
  • Ovarian Carcinoma
  • Ovary Neoplasm
  • Squamous Cell Lung Cancer
  • Adenocarcinoma of Lung
  • Adenosquamous Cell Lung Cancer

Keywords

  • adoptive cell therapy
  • neoantigen
  • T cell receptor
  • T lymphocyte
  • TCR-engineered T cells
  • cell therapy
  • immunotherapy
  • IL-2
  • Gene therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA type restriction combination is available in Alaunos' Clinical TCR library
  2. Patients who have previously received at least one line of standard systemic therapy for their advanced/ cancer and have either progressed, recurred, or were intolerant to the previous treatment. Specifically:

    • Subgroup 1. Gynecologic cancers (i.e., ovarian or endometrial):

      1. Ovarian cancer
      2. Endometrial cancer
    • Subgroup 2. Colorectal cancer
    • Subgroup 3. Pancreatic cancer
    • Subgroup 4. Non-small cell lung cancer (NSCLC)
    • Subgroup 5. Cholangiocarcinoma
  3. Patients must have evaluable or per 1.1 with at least one lesion that can be measured that is not the biopsied lesion.
  4. Patients must be able to provide written .
  5. Patients must be age ≥ 18 years.
  6. Clinical Performance Status of 0 or 1. Approval from the Alaunos Medical Monitor is required for ECOG of 2.
  7. Patient must be willing and able to provide written informed consent for the long-term follow-up protocol (TCR001-202) for up to 15 years post TCR-T Cell drug product infusion per FDA requirements.
  8. Adequate bone marrow reserves as assessed by the following hematology laboratory criteria:
  9. Adequate major organ system function
  10. A must have elapsed since completion of any prior systemic therapy, and apheresis with guidelines as follows (windows other than what is listed below should be allowed only after consultation with the Medical Monitor); subjects' non-hematologic toxicities from any prior systemic therapy must have recovered to ≤ Grade 1 (with the exception of neuropathy and alopecia) or baseline prior to starting the protocol's therapy.
  11. Patients may have undergone minor surgical procedures or limited-field radiotherapy provided any major organ toxicities have recovered to ≤ Grade 1.
  12. Female patients must not be pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known active
  2. Concurrent systemic therapy
  3. Any form of primary immunodeficiency
  4. Patients who have decreased immune competence
  5. History of severe immediate reaction to cyclophosphamide, fludarabine, aldesleukin or bendamustine
  6. Severe chronic respiratory condition
  7. History of a bleeding disorder or unexplained major bleeding diathesis
  8. Arm B Criteria only: patient history which in the judgment of the principal investigator (PI) would compromise the subject's ability to tolerate high-dose aldesleukin;
  9. Any major bronchial occlusion or bleeding not amenable to palliation.
  10. Patients with psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.
  11. Participants with known active, uncontrolled bacterial, fungal, or viral infection
  12. Patients with a prior history or concurrent
  13. Active unstable or clinically significant medical condition
  14. History of any major cardiovascular conditions within the past 6 months
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    TCR-T Cell Drug Product

    Phase I: Dose-escalation of TCR-T Cell Drug Product Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study

    Biological: Neoantigen specific TCR-T cell drug product

  • Experimental
    TCR-T Cell Drug Product with Aldesleukin (IL-2)

    Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2) Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study

    Biological: Neoantigen specific TCR-T cell drug product · Biological: Aldesleukin (IL-2)

Interventions

  • BiologicalNeoantigen specific TCR-T cell drug product

    Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D

  • BiologicalAldesleukinStudies of AldesleukinAldesleukin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To support growth and activation of TCR-T cell drug product

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year.

    Time frame: From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.

  2. Frequency of Dose Limiting Toxicities

    Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From Day 0 to Day 28 post TCR-T cell drug product infusion.

  3. Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)

    MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A.

    Time frame: From Day 0 to Day 28 post TCR-T cell drug product infusion.

Secondary outcomes

  1. Feasibility of TCR-T Cell Drug Product Manufacturing

    Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures.

    Time frame: From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks

  2. TCR-T Cell Persistence

    Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure.

    Time frame: Baseline through nominal Month 18 post-infusion.

  3. Percent Change in TCR-T Cell Count From Post Dose to Day 28

    For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%).

    Time frame: Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.

  4. Final T-Cell Count in Released TCR-T Cell Drug Product

    Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used.

    Time frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).

  5. Viability of Released TCR-T Cell Drug Product

    Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product.

    Time frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).

  6. Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample

    Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable.

    Time frame: From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.

07

Results

Posted Nov 10, 2025
Limitations and caveats
The study ended for business reasons during Phase I Arm A: 8 participants were treated, Arm B and Phase II were not started, and the MTD/RP2D was not determined. Analyses are descriptive. 2 of 7 participants assigned to DL2 received DL1-range doses. No participant received the prophylactic tocilizumab added by Amendment 4. The database was locked without full data cleaning, and long-term follow-up ended early. Persistence reflects available samples.

Participant flow

34 participants signed consent forms, 14 participants were apheresed, and 8 participants were lymphodepleted and per the protocol definition were considered enrolled. 8 were treated with TCR-T cells.

Participant flow — Overall Study
MilestoneAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ )Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Started1130
Apheresis 11130
Apheresis 2020
Manufacture 11100
Manufacture 2020
Lymphodepletion (enrollment)170
Tcr infusion170
Assigned dose level 2 but received dose level 1 due to manufacturing process020
Completed170
Not completed060
Withdrew: Apheresed but not administered tcr-t cells due to manufacturing failure020
Withdrew: Apheresed but not administered tcr-t cells due to participant developed brain metastases010
Withdrew: Apheresed but not administered tcr-t cells due to early termination of study020
Withdrew: Apheresed but not administered tcr-t cells due to participant cerebrovascular accident010

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year.

Time frame:
From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events
participantsAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Any TEAE17—
Drug-related TEAE17—
Drug-related Grade 3 or higher TEAE16—
TEAE leading to death00—
Treatment-emergent SAE12—
PrimaryFrequency of Dose Limiting Toxicities

Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Time frame:
From Day 0 to Day 28 post TCR-T cell drug product infusion.
Reported as:
Count of participants · Participants
Frequency of Dose Limiting Toxicities
ParticipantsAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Frequency of Dose Limiting Toxicities00—
PrimaryDetermination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)

MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A.

Time frame:
From Day 0 to Day 28 post TCR-T cell drug product infusion.
Reported as:
Number · Dose level of TCR-T cells infused
Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Dose level of TCR-T cells infusedAll Dose Levels (DLT-Evaluable Population)
Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)NA
SecondaryFeasibility of TCR-T Cell Drug Product Manufacturing

Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures.

Time frame:
From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks
Reported as:
Number · participants
Feasibility of TCR-T Cell Drug Product Manufacturing
participantsApheresed Participants (Feasibility Population)
Unable to be apheresed for logistical or medical reasons0
Apheresis performed but manufacturing not initiated due to study closure.2
Infused successfully at the planned dose after 1 manufacturing round.6
Infused at a lower dose than planned after 1 manufacturing round.1
Infused at a lower dose than planned after 2 manufacturing rounds.1
Participants who were manufacturing failures after 2 manufacturing rounds1
Manufacturing failure after 1 manufacturing round; not infused1
Insufficient cell yield after 1 manufacturing round and new brain metastases; not infused1
Low expansion on small-scale testing and stroke after leukapheresis; not infused1
SecondaryTCR-T Cell Persistence

Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure.

Time frame:
Baseline through nominal Month 18 post-infusion.
Reported as:
Median · copies/1x10^6 cells
TCR-T Cell Persistence
copies/1x10^6 cellsAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Baseline (1 week prior to infusion)NANA (0 to 0)—
Predose Day 0NANA (0 to 0)—
Post Dose Day 04,240,0002,570,000 (779,000 to 3,970,000)—
Day 13,190,000373,000 (20,700 to 1,710,000)—
Day 22,640,000804,000 (61,400 to 2,270,000)—
Day 43,500,000570,000 (18,700 to 3,400,000)—
Day 7743,000101,000 (5,320 to 3,730,000)—
Day 10674,000112,000 (14,200 to 961,000)—
Day 14984,000112,000 (7,900 to 938,000)—
Day 21504,00041,300 (1,140 to 489,000)—
Day 28404,00090,000 (5,450 to 297,000)—
Week 6197,00035,600 (3,330 to 203,000)—
Week 12163,00027,200 (1,960 to 121,000)—
Month 3—42,400—
Month 688,1008,120—
Month 15—NA—
Month 18—NA—
SecondaryPercent Change in TCR-T Cell Count From Post Dose to Day 28

For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%).

Time frame:
Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
Reported as:
Median · percent change from peak post dose
Percent Change in TCR-T Cell Count From Post Dose to Day 28
percent change from peak post doseAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Percent Change in TCR-T Cell Count From Post Dose to Day 28-90.5-96.0 (-100 to -91.1)—
SecondaryFinal T-Cell Count in Released TCR-T Cell Drug Product

Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used.

Time frame:
At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Reported as:
Median · 10^9 cells
Final T-Cell Count in Released TCR-T Cell Drug Product
10^9 cellsAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ )Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Total viable cells10.025.0 (1.4 to 69.2)—
Final mTCR-positive cells9.020.7 (1.0 to 64.0)—
SecondaryViability of Released TCR-T Cell Drug Product

Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product.

Time frame:
At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Reported as:
Median · Percent viable cells
Viability of Released TCR-T Cell Drug Product
Percent viable cellsAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ )Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Viability of Released TCR-T Cell Drug Product95.187.3 (76.7 to 92.8)—
SecondaryProtocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample

Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable.

Time frame:
From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.
Reported as:
Median · Days
Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample
DaysAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ )Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample17286 (21 to 180)—

Adverse events

Collected over From initiation of lymphodepletion until the participant's final study visit, up to approximately 1 year after TCR-T cell infusion.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)1/1 (100%)1/1 (100%)1/1 (100%)
Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)6/7 (85.7%)2/7 (28.6%)7/7 (100%)
Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)———
Most frequent serious events
Most frequent serious events
EventAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Cytokine release syndromeImmune system disorders1/12/7—
HypotensionVascular disorders1/10/7—
HypoxiaRespiratory, thoracic and mediastinal disorders1/10/7—
Sinus tachycardiaCardiac disorders1/10/7—
ThrombocytopeniaBlood and lymphatic system disorders1/10/7—
AnaemiaBlood and lymphatic system disorders1/10/7—
Febrile neutropeniaBlood and lymphatic system disorders1/10/7—
Most frequent other events
Showing 10 of 89
Most frequent other events
EventAssigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)
Abdominal distensionGastrointestinal disorders1/10/7—
Activated partial thromboplastin time prolongedInvestigations1/14/7—
Alanine aminotransferase increasedInvestigations1/14/7—
AnaemiaBlood and lymphatic system disorders1/17/7—
Aspartate aminotransferase increasedInvestigations1/12/7—
Blood fibrinogen increasedInvestigations1/12/7—
ChillsGeneral disorders1/13/7—
ConstipationGastrointestinal disorders1/12/7—
CoughRespiratory, thoracic and mediastinal disorders1/13/7—
COVID-19Infections and infestations1/10/7—

Baseline characteristics

Safety Analysis Set: all 8 participants who received lymphodepletion and a TCR-T cell infusion. The 6 participants who underwent leukapheresis but were not enrolled or infused are not included.

Age, Continuous
Age, Continuous(years)Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)Total
Median3453 (50 to 65)—53 (34 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)Total
Female1405
Male0303
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)Total
Hispanic or Latino10—1
Not Hispanic or Latino07—7
Unknown or Not Reported00—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)Total
American Indian or Alaska Native00—0
Asian01—1
Native Hawaiian or Other Pacific Islander00—0
Black or African American00—0
White14—5
More than one race00—0
Unknown or Not Reported02—2
Region of Enrollment
Region of Enrollment(participants)Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)Total
United States17—8
Tumor Type
Tumor Type(Participants)Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹)Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹)Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹)Total
Colorectal0404
Pancreatic0303
Non-small cell lung cancer1001
08

Study locations

1 site
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study. J Clin Oncol. 2023;41(16_suppl):2547. doi:10.1200/JCO.2023.41.16_suppl.2547
  • Levy PL, Gros A. Fast track to personalized TCR T cell therapies. Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9. PubMed 35537408 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2022 to primary completion in Sep 2023, 17 months.

Results were first posted in Nov 2025, 2 years 1 month after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Aug 2023 → Sep 2023 and completion Aug 2023 → Oct 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Jan 18, 2022
StartActual
Apr 4, 2022
Primary completionActual
Sep 30, 2023was Aug 2023
CompletionActual
Oct 11, 2023was Aug 2023
Results first posted
Nov 10, 2025
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Why stopped
Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.
Nov 9, 2026
Results
Posted results revised
revised Nov 9, 2026
Primary completion
Aug 14, 2023→Sep 30, 2023
Nov 9, 2026
Study completion
Aug 14, 2023→Oct 11, 2023
Nov 9, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionDetermination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D): how it is measured was reworded
Nov 9, 2026
Publications
Results publication added: Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by soli…
Nov 9, 2026
Secondary outcomes
2 time frame changed, 3 added, 3 description edited
What changed in the outcomes
  • AddedFinal T-Cell Count in Released TCR-T Cell Drug ProductTime frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
  • AddedViability of Released TCR-T Cell Drug ProductTime frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
  • AddedProtocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN SampleTime frame: From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.
  • Time frameTCR-T Cell PersistenceBaseline through Month 18 post-infusion. → Baseline through nominal Month 18 post-infusion.
  • Time framePercent Change in TCR-T Cell Count From Post Dose to Day 28Post-dose through Day 28 → Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
  • DescriptionFeasibility of TCR-T Cell Drug Product Manufacturing: how it is measured was reworded
  • DescriptionPercent Change in TCR-T Cell Count From Post Dose to Day 28: how it is measured was reworded
  • DescriptionTCR-T Cell Persistence: how it is measured was reworded
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Why stopped Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.
    Posted results revised
    Publications Results publication added: Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by soli…
    Primary completion Aug 14, 2023→Sep 30, 2023
    Study completion Aug 14, 2023→Oct 11, 2023
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDetermination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D): how it is measured was reworded
    Secondary outcomes 2 time frame changed, 3 added, 3 description edited
    What changed in the outcomes
    • AddedFinal T-Cell Count in Released TCR-T Cell Drug ProductTime frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
    • AddedViability of Released TCR-T Cell Drug ProductTime frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
    • AddedProtocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN SampleTime frame: From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.
    • Time frameTCR-T Cell PersistenceBaseline through Month 18 post-infusion. → Baseline through nominal Month 18 post-infusion.
    • Time framePercent Change in TCR-T Cell Count From Post Dose to Day 28Post-dose through Day 28 → Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
    • DescriptionFeasibility of TCR-T Cell Drug Product Manufacturing: how it is measured was reworded
    • DescriptionPercent Change in TCR-T Cell Count From Post Dose to Day 28: how it is measured was reworded
    • DescriptionTCR-T Cell Persistence: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05194735
Responsible party
Sponsor
First posted
Jan 18, 2022
Start date
Apr 4, 2022
Primary completion
Sep 30, 2023
Completion
Oct 11, 2023
Results posted
Nov 10, 2025
Last update
Nov 9, 2026

Study contacts

Scott Kopetz, MD, PhD
principal investigator · MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aldesleukin

Start the discussion